IRLAB Therapeutics AB (IRLAB A) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Cantargia AB

Medivir AB

IRLAB Therapeutics AB

Orexo AB

InDex Pharmaceuticals Holding AB

Cereno Scientific AB

Diamyd Medical AB

SynAct Pharma AB

Guard Therapeutics International AB

Initiator Pharma A/S

Kancera AB

Why is IRLAB Therapeutics AB ?

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -80.29%, its profits have risen by 13.5%

Below par performance in long term as well as near term

Along with generating -80.29% returns in the last 1 year, the stock has also underperformed OMX Stockholm 30 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is IRLAB Therapeutics AB for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

IRLAB Therapeutics AB

-80.29%

-0.75

110.49%

OMX Stockholm 30

8.01%

0.44

18.11%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

144.04%

EBIT Growth (5y)

3.39%

EBIT to Interest (avg)

-41.40

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-5.36

Sales to Capital Employed (avg)

0.65

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

2.69%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-8.24

EV to EBIT

-2.51

EV to EBITDA

-2.63

EV to Capital Employed

-33.71

EV to Sales

3.28

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company

OPERATING CASH FLOW(Y)

Highest at SEK -21.05 MM

NET PROFIT(HY)

Higher at SEK -39.36 MM

NET SALES(9M)

Higher at SEK 56.21 MM

DEBT-EQUITY RATIO (HY)

Lowest at -478.04 %

DEBTORS TURNOVER RATIO(HY)

Highest at 7.41%

-21What is not working for the Company

PRE-TAX PROFIT(Q)

At SEK -33.97 MM has Fallen at -63.45%

NET PROFIT(Q)

At SEK -33.97 MM has Fallen at -63.45%

ROCE(HY)

Lowest at -191.89%

RAW MATERIAL COST(Y)

Grown by 67,938% (YoY

CASH AND EQV(HY)

Lowest at SEK 155.52 MM

INTEREST(Q)

Highest at SEK 5.57 MM

Here's what is working for IRLAB Therapeutics AB

Net Sales

At SEK 56.21 MM has Grown at 4,815.69%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (SEK MM)

Operating Cash Flow

Highest at SEK -21.05 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (SEK MM)

Debt-Equity Ratio

Lowest at -478.04 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 7.41%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Net Sales

Higher at SEK 56.21 MM

than preceding 12 month period ended Mar 2025

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

Net Sales (SEK MM)

Here's what is not working for IRLAB Therapeutics AB

Pre-Tax Profit

At SEK -33.97 MM has Fallen at -63.45%

over average net sales of the previous four periods of SEK -20.78 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (SEK MM)

Net Profit

At SEK -33.97 MM has Fallen at -63.45%

over average net sales of the previous four periods of SEK -20.78 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (SEK MM)

Interest

At SEK 5.57 MM has Grown at 87.85%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (SEK MM)

Interest

Highest at SEK 5.57 MM

in the last five periods and Increased by 87.85% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (SEK MM)

Cash and Eqv

Lowest at SEK 155.52 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 67,938% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales